Market Overview

Morgan Stanley Reiterates Overweight on Biogen Idec Following AlphaWise Survey

Share:
Related BIIB
Is More M&A On The Way For Large-Cap Biotechs?
With The Teva Money, Allergan Could Engage In 'Large M&A' Next: Evercore ISI
Mixed Biotech Earnings put These ETFs in Focus - ETF News And Commentary (Zacks)

In a report published Friday, Morgan Stanley analyst Marshall Urist reiterated an Overweight rating on Biogen Idec (NASDAQ: BIIB).

In the report, Urist noted, “Our AlphaWise survey of 121 neurologists in the US and Europe (performed in the month prior to Tecfidera approval) supports a strong launch, $4B+ in sales potential for Biogen's Tecfidera, and our Overweight rating. Roughly half of patients are expected to be on oral therapies within 4-6 years. This implies $4B+ in global sales assuming Tecfidera gains at least 50-60% of the oral segment, which is at the high end of long-term consensus of $3.4-4B. Of note, ABCR share declines from ~80% to ~30% while the high-efficacy segment gains 15% share over this period.”

Biogen Idec closed on Thursday at $217.30.

Latest Ratings for BIIB

DateFirmActionFromTo
Jul 2015BairdDowngradesOutperformNeutral
Jul 2015Morgan StanleyMaintainsOverweight
Jul 2015BernsteinUpgradesMarket PerformOutperform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BIIB)

Get Benzinga's Newsletters